This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. NOTE: Pilot Project Investigator: Shawn D. Spencer, PhD, former assistant professor of pharmaceutics, has accepted a position as a Pharmacokineticist at NIH/NCI effective February 3, 2011. ABSTRACT: Chronic Fatigue Immune Dysfunction Syndrome (CFIDS) is a severely debilitating disorder for which there is presently no cure. Treatment options are limited, and to date, no drugs have been developed specifically for CFIDS. Our long range research goals are 1) to understand fully the mechanisms of CFIDS disease progression, and 2) the development of improved therapeutic intervention strategies for CFIDS. The etiology, pathogenesis, and mechanisms of immune dysfunction in CFIDS are all poorly understood;however there is growing evidence that Human Herpes Virus-6 (HHV-6) infection may play a role in CFIDS pathogenesis. Our hypotheses are: 1) HHV-6 establishes persistent infection in monocytes through alterations in host-cell proteins involved in immune response and 2) Targeted nanoparticulate-formulation delivery systems of Ribonucleotide Reductase Inhibitors are effective against HHV-6 DNA replication. The primary rationale is that viruses often evade host defense through proteolysis of immune response mediators, and thus raises the possibility that HHV's are responsible for degradation of STAT1 and native RNase-L in CFIDS. Moreover, available treatments for HHV-6 active infection are limited. We will test our hypothesis in this pilot project through the following 3 Specific Aims: (1) Obtain a Protein Signature of the primary structures and molecular weights of host cellular and viral proteins expressed in cell-line models (HL-60 and U937 leukemia cells) of productive versus latent HHV-6 infection of human monocytes of PBMCs. (2) Determine the susceptibility of HHV-6 infected and non-infected HL-60 and U937 leukemia cell models to Ribonucleotide Reductase inhibition. (3) Determine in-vitro the pharmacology and toxicity of nanocapsules of HHV-6 DNA replication inhibitors in Herpes-virus infected HL-60 and U937 leukemia cell models. Successful completion of the aims in this pilot study will enhance the long-term developmental objectives of the PI, while obtaining sufficient Preliminary Data for investigator-initiated grant applications. Supported by NIH/NCRR/RCMI G12RR03020.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12RR003020-27
Application #
8357116
Study Section
Special Emphasis Panel (ZRR1-RI-3 (01))
Project Start
2011-06-01
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
27
Fiscal Year
2011
Total Cost
$117,045
Indirect Cost
Name
Florida Agricultural and Mechanical University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
623751831
City
Tallahassee
State
FL
Country
United States
Zip Code
32307
Poku, Rosemary A; Salako, Olufisayo O; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells. Am J Cancer Res 7:1515-1527
Ntantie, Elizabeth; Fletcher, Jerrine; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer. Oncotarget 8:31726-31744
Mazzio, Elizabeth A; Soliman, Karam F A (2017) HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells. Cancer Genomics Proteomics 14:17-33
Mazzio, Elizabeth A; Li, Nan; Bauer, David et al. (2016) Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med 16:467
Nkembo, Augustine T; Ntantie, Elizabeth; Salako, Olufisayo O et al. (2016) The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety. Oncotarget 7:68194-68205
Boakye, Cedar H A; Patel, Ketan; Doddapaneni, Ravi et al. (2016) Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. Colloids Surf B Biointerfaces 143:156-167
Odewumi, Caroline O; Latinwo, Lekan M; Ruden, Michael L et al. (2016) Modulation of cytokines and chemokines expression by NAC in cadmium chloride treated human lung cells. Environ Toxicol 31:1612-1619
Shah, Punit P; Desai, Pinaki R; Boakye, Cedar H A et al. (2016) Percutaneous delivery of ?-melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis. J Drug Target 24:537-47
Ofori, Edward; Zhu, Xue Y; Etukala, Jagan R et al. (2016) Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors. Bioorg Med Chem 24:5730-5740
Mochona, Bereket; Jackson, Timothy; McCauley, DeCoria et al. (2016) Synthesis and Cytotoxic Evaluation of Pyrrole Hetarylazoles Containing Benzimidazole/Pyrazolone/1,3,4-Oxadiazole Motifs. J Heterocycl Chem 53:1871-1877

Showing the most recent 10 out of 202 publications